The present invention provides a compound for use in reducing liver fat in a subject, wherein the compound is selected from: (i) (R)-3-hydroxybutyrate； (ii) an ester of (R)-3-hydroxybutyrate； and (iii) an oligomer obtainable by polymerising (R)-3-hydroxybutyrate moieties； or a pharmaceutically acceptable salt or solvate thereof. The compound is particularly useful in subjects suffering from a fatty liver. The compound can be used to treat non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) or non-alcoholic fatty liver (NAFL).
